Equities

Medicon Hellas SA

Medicon Hellas SA

Actions
  • Price (EUR)2.79
  • Today's Change0.06 / 2.20%
  • Shares traded--
  • 1 Year change-20.06%
  • Beta--
Data delayed at least 15 minutes, as of Jun 28 2024 20:35 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medicon Hellas SA is a Greece-based company active in the health equipment sector. Its activities include research and development, production, and import and export of diagnostic products; the development of laboratory information systems; the import and distribution of in vitro diagnostics and automated analytical systems, such as Olympus for clinical chemistry, immunochemistry and lab automation, and Nihon Kohden for hematology, and the provision of cosmetic and body care products, such as make-up, anti-ageing and skin care products under the brand name Miss Beaute. Its laboratory information systems products include: Gi-Lab, which is a management system for medical laboratories; Gi-Maxima, a management program for medical centers, and Gi-Blood, which is an application that helps to connect various blood donation networks. On December 6, 2013, it merged by absorption of its subsidiary, Medicon Ltd.

  • Revenue in EUR (TTM)19.86m
  • Net income in EUR2.06m
  • Incorporated1988
  • Employees98.00
  • Location
    Medicon Hellas SAMelitona 5-7, GerakasATHINA 153 44GreeceGRC
  • Phone+30 2 106606000
  • Fax+30 2 106612666
  • Websitehttps://www.mediconsa.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.